Higher US generic drugs user fee for foreign units 'discriminatory, anti-competitive', say Indian firms
This article was originally published in SRA
Indian firms believe that the US Food and Drug Administration's proposed generic drug user fee plan, under which foreign facilities will be required to pay more for inspections, is discriminatory and unwarranted1.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.